Emerald Mutual Fund Advisers Trust Sells 4,387 Shares of Guardant Health, Inc. $GH

Emerald Mutual Fund Advisers Trust reduced its position in Guardant Health, Inc. (NASDAQ:GH) by 0.8% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 519,545 shares of the company’s stock after selling 4,387 shares during the period. Guardant Health accounts for about 2.3% of Emerald Mutual Fund Advisers Trust’s holdings, making the stock its 3rd biggest holding. Emerald Mutual Fund Advisers Trust’s holdings in Guardant Health were worth $47,990,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. V Square Quantitative Management LLC purchased a new stake in Guardant Health in the fourth quarter valued at approximately $27,000. Chesapeake Asset Management LLC purchased a new position in Guardant Health in the 4th quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Guardant Health in the fourth quarter valued at about $31,000. Elyxium Wealth LLC acquired a new position in Guardant Health during the 4th quarter worth approximately $35,000. Finally, Parallel Advisors LLC lifted its holdings in Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after acquiring an additional 219 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have commented on GH shares. Guggenheim boosted their target price on Guardant Health from $135.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Barclays lifted their target price on shares of Guardant Health from $120.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. JPMorgan Chase & Co. raised their target price on shares of Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. Finally, Mizuho lifted their price objective on Guardant Health from $135.00 to $175.00 and gave the company an “outperform” rating in a research note on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average target price of $155.70.

Guardant Health Trading Down 1.0%

Shares of NASDAQ GH opened at $158.40 on Tuesday. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $174.08. The company has a market cap of $21.00 billion, a P/E ratio of -46.73 and a beta of 1.59. The stock has a fifty day moving average price of $128.92 and a 200 day moving average price of $108.75.

Insiders Place Their Bets

In related news, Director Musa Tariq sold 1,951 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $131.16, for a total transaction of $255,893.16. Following the sale, the director directly owned 11,048 shares in the company, valued at approximately $1,449,055.68. This trade represents a 15.01% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 143,028 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $151.54, for a total value of $21,674,463.12. Following the transaction, the chief executive officer directly owned 1,881,336 shares in the company, valued at $285,097,657.44. This trade represents a 7.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 708,681 shares of company stock valued at $90,566,438. Company insiders own 5.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.